Esperion Therapeutics (ESPR) Treasury Shares (2015 - 2026)

Esperion Therapeutics has reported Treasury Shares for 7 years, with the latest figure at $55.0 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares changed 0.0% year-over-year to $55.0 million; the trailing twelve-month figure through Mar 2026 stood at $55.0 million (changed 0.0% YoY), and the FY2025 full-year result was $55.0 million, changed 0.0% from the prior year.
• Treasury Shares for Q1 2026 stood at $55.0 million, roughly flat from $55.0 million in the prior quarter.
• The five-year high for Treasury Shares was $10.9 million in Q1 2026, with the low at $2.0 million in Q1 2022.
• Historically, Treasury Shares has averaged $3.3 million across 5 years, with a median of $2.0 million in 2022.
• The largest YoY upside for Treasury Shares was 0.0% in 2022 against a maximum downside of 0.0% in 2022.
• Esperion Therapeutics' Treasury Shares stood at $55.0 million in 2022, then changed by 0.0% to $55.0 million in 2023, then changed by 0.0% to $55.0 million in 2024, then changed by 0.0% to $55.0 million in 2025, then changed by 0.0% to $55.0 million in 2026.
• The last three Treasury Shares figures came in at $55.0 million (Q1 2026), $55.0 million (Q4 2025), and $55.0 million (Q3 2025), per Business Quant data.